Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Income from Continuing Operations (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Income from Continuing Operations for 12 consecutive years, with 30625000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 232.94% year-over-year to 30625000.0, compared with a TTM value of 99878000.0 through Sep 2025, down 1155.06%, and an annual FY2024 reading of 35129000.0, down 11.37% over the prior year.
  • Income from Continuing Operations was 30625000.0 for Q3 2025 at Avalo Therapeutics, down from 20765000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 98463000.0 in Q2 2024 and bottomed at 121290000.0 in Q1 2024.
  • Average Income from Continuing Operations over 5 years is 13538578.95, with a median of 13149000.0 recorded in 2025.
  • Peak annual rise in Income from Continuing Operations hit 1301.79% in 2024, while the deepest fall reached 1118.38% in 2024.
  • Year by year, Income from Continuing Operations stood at 19131000.0 in 2021, then skyrocketed by 48.71% to 9812000.0 in 2022, then rose by 16.75% to 8168000.0 in 2023, then crashed by 332.65% to 35339000.0 in 2024, then increased by 13.34% to 30625000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for AVTX at 30625000.0 in Q3 2025, 20765000.0 in Q2 2025, and 13149000.0 in Q1 2025.